Learn How to Tell the Difference

Differentiation depends on the phenomenology of the symptoms, their timing, and how the movements change in response to increasing or decreasing antipsychotic doses or adding anticholinergics.2-4,7-10

Tardive Dyskinesia

  • Nonrhythmic but may be repetitive6

  • Choreoathetoid movement5,7

  • Chewing movements6

  • Pouting6

  • Opening/closing of mouth6

  • Tongue protrusion6

  • Abnormal blinking8

  • “Piano-playing” fingers9,10

Drug-Induced Parkinsonism

  • Rhythmic tremor

  • Muscle rigidity

  • Shuffling gait

  • Bradykinesia

  • Pouting6

  • Salivation

  • Abnormal blinking


Ask the Faculty

How do you differentiate among extrapyramidal symptoms (EPS) disorders? In particular, how can you tell the difference between drug-induced parkinsonism and TD?

The Biology of Differentiation

It is believed that TD results from changes to dopamine D2 receptors after exposure to dopamine receptor blocking agents (DRBAs). These agents block D2 receptors, and as a result of that blockade, these receptors are sensitized or upregulated, increasing dopaminergic neurotransmission.11 This hyperdopaminergic mechanism is the opposite of the hypodopaminergic mechanism of a movement disorder sometimes misdiagnosed as TD: drug-induced parkinsonism. Because these mechanisms are so different, it is very important to accurately diagnose TD before selecting a treatment.4,7,12

Who Is at Risk?

Anyone with a history of DRBA use is at risk for developing TD.1,2,13 DRBAs include:

  • First- and second-generation antipsychotics used for schizophrenia, bipolar disorder, or major depressive disorder, or for agitation related to dementia1,13-15
  • Antiemetics and other drugs used to treat dyspepsia or nausea and vomiting1,13-15

Even if a patient is not currently taking a DRBA, cumulative exposure and potency of D2 blockade increase risk of TD, as does a history of drug-induced movement disorders. Additional patient risk factors include being age 50 years or older, having a diagnosis of a mood disorder, being postmenopausal, and substance abuse. Female patients are at greater risk for tardive dyskinesia.16-18


Risk Factors for Tardive Dyskinesia

Is My Patient at Higher Risk?

TD Risk Factors
Download the full presentation on Risk Factors for Tardive Dyskinesia

You've just learned:

  • TD is a distinct medication-induced movement disorder that is sometimes confused with others
  • Differential diagnosis must consider symptom phenomenology, timing, and how the movements change in response to antipsychotic dose and anticholinergics
  • The pathophysiology is different between TD and other medication-induced movement disorders
  • There are several risk factors when it comes to TD, including the age of the patient and the medications they have been treated with


Now learn what treatment guidelines recommend

References


  1. Fahn S, et al, eds. Principles and Practice of Movement Disorders. 2nd ed. Saunders; 2011:415-446.

  2. Hauser RA, et al. CNS Spectr. 2022;27(2):208-217.

  3. Ward KM, Citrome L. Neurol Ther. 2018;7(2):233-248.

  4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed., text rev. American Psychiatric Association; 2022.

  5. Caroff S, et al. Neurol Clin. 2011;29(1):127-148, viii.

  6. Caroff SN, et al. Psychiatr Clin North Am. 2016;39(3):391-411.

  7. American Psychiatric Association. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. 3rd ed. American Psychiatric Association; 2021.

  8. Lumetti S, et al. Case Rep Dent. 2016;2016:7167452.

  9. Tarsy D. Curr Treat Options Neurol. 2000;2(3):205-214.

  10. Polychronis, S., Nasios, G., Dardiotis, E., Messinis, L., & Pagano, G. Healthcare (Basel, Switzerland), 2022;10(3):516.

  11. Stahl SM. CNS Spectr. 2017;22(6):427-434.

  12. Stahl S. Stahl’s Essential Pharmacology. 4th ed. Cambridge University Press; 2013:145-252.

  13. Yohanna D, et al. JAMA. 2017;318(11):1057-1058.

  14. Lerner P. Psychiatry Clin Neurosci. 2015;69(6):321-334.

  15. Meyer JM. In: Brunton LL, et al, eds. Goodman & Gilman's: The Pharmacological Basis of Therapeutics. 13th ed. McGraw-Hill; 2018.

  16. Miller DD, et al. Schizophr Res. 2005;80:33-43.

  17. Woerner MG, et al. Am J Psychiatry. 1998;155(11):1521-1528.

  18. Turrone P, Seeman MV, Silvestri S. Can J Psychiatry. 2000;45(3):288-290.